Lupin signs patent license agreement with Abbott

Pharma major, Lupin and its subsidiaries, Lupin Pharmaceuticals, Inc and Lupin Atlantis Holding S.A., have entered a license agreement with Abbott Laboratories and Laboratoires Fournier S.A

Pharma major, Lupin and its subsidiaries, Lupin Pharmaceuticals, Inc and Lupin Atlantis Holding S.A., have entered a license agreement with Abbott Laboratories and Laboratoires Fournier S.A. for various Abbott patents for Antara (Fenofibrate) Capsules.

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

On Tuesday, Lupin ended 1.09% up at Rs419.20 on the Bombay Stock Exchange, while the benchmark Sensex ended 0.20% to 19,545.35.

User

Venus Remedies completes Phase I & II clinical trials of cancer detection molecule—Tumatrek

Tumatrek, a unique and cost effective diagnostic tool for cancer can also detect malignancy even through a simple X-ray

Venus Remedies, a research based pharma MNC has successfully completed Phase I & II clinical trial for VRP1620, a cancer detection molecule. The clinical study has shown excellent results in detection of breast cancer. With this drug detection of breast cancer would be possible even with a simple X-ray using dye and the sensitivity of other detection devices such as coloured doppler, PET would be increased several times.

Dr Manu Chaudhary, Research Director of the company said, "VRP 1620 (Tumatrek) is a unique and cost effective diagnostic tool for cancer which can also detect malignancy even through X-ray. It can detect cancer at lesser cost and at primary stage itself." By detection of cancer at early stage it can increase the cure rate. Scientists believe that after Phase III trials of this product VRP-1620 may also help in locating proliferation of cancer site. There are lots of opportunities where the usage of this product can be extrapolated for the benefit of humanity.

A team of scientists from Venus Medicines Research Center (VMRC), R&D wing of the company were working for past couple of years on a novel peptide VRP 1620, which is highly selective ETB receptor agonist and is involved in selective vasodilation in solid tumors. "Phase III will be completed this year only and product will be ready for market launch in early 2012." Dr. Chaudhary added.

Venus Remedies has completed and submitted the report of Phase I & II study on breast cancer patients for VRP 1620 after due permission from IND Committee and DCGI, Govt. of India. This clinical study documented the pharmacokinetic profile and appropriate dose range for the drug. It also described the efficacy for its use as a diagnostic agent for breast cancer. The efficacy was gauged by observing increase in diameter and the corresponding change in resistive index of tumor vessel.

On Tuesday, Venus Remedies ended 1.08% up at Rs220.25 on the Bombay Stock Exchange, while the benchmark Sensex ended 0.20% to 19,545.35.

User

Aventis Pharma Q1 net up 40.16% to Rs50.6 crore

Aventis Pharma net profit rose 40.16% to Rs50.6 crore in the first quarter ended 31 March 2011, vis-a-vis Rs36.1 crore during the same period last fiscal

Aventis Pharma net profit rose 40.16% to Rs50.6 crore in the first quarter ended 31 March 2011, vis-a-vis Rs36.1 crore during the same period last fiscal.

In a filing to the Bombay Stock Exchange (BSE), the company's net sales rose to Rs 276.3 crore during the first quarter compared with Rs 251.4 crore in the same period of the previous fiscal.

The board meeting held on 16 February 2011, had recommended a final dividend of Rs23 per share of Rs10 face value for the year ended 31 December 2010. It had also recommended a special one-time dividend of Rs28 per equity share of Rs10.

On Tuesday, Aventis Pharma ended 4.57% up at Rs2,000.75 on the Bombay Stock Exchange, while the benchmark Sensex ended 0.20% to 19,545.35.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)